Pfizer gets first approval, in UK, for Xeljanz follow-up Cib...

Pfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

FDA sets April verdict for Pfizer’s “underestimated” atopic ...

Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert Bourla believes hasn’t been given the credit

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum